Jade Biosciences, Inc. (NASDAQ:JBIO) Receives $19.75 Average Price Target from Analysts

Jade Biosciences, Inc. (NASDAQ:JBIO) has been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $19.75.

A number of brokerages recently weighed in on JBIO. Weiss Ratings restated a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 22nd. BTIG Research initiated coverage on shares of Jade Biosciences in a research note on Thursday, October 9th. They issued a “buy” rating and a $28.00 price target for the company. Guggenheim raised their price objective on shares of Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Finally, Wall Street Zen upgraded Jade Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th.

Jade Biosciences Trading Down 1.4%

JBIO opened at $16.22 on Tuesday. The business’s 50 day moving average is $12.39 and its 200-day moving average is $9.87. The stock has a market cap of $799.81 million, a PE ratio of -1.45 and a beta of 1.04. Jade Biosciences has a twelve month low of $6.57 and a twelve month high of $100.10.

Jade Biosciences (NASDAQ:JBIO) last posted its earnings results on Friday, November 14th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. bought a new stake in Jade Biosciences in the second quarter worth about $17,703,000. Versant Venture Management LLC acquired a new position in shares of Jade Biosciences in the 2nd quarter worth approximately $15,243,000. Soleus Capital Management L.P. bought a new stake in shares of Jade Biosciences in the 2nd quarter worth approximately $7,959,000. Geode Capital Management LLC acquired a new stake in Jade Biosciences during the second quarter valued at approximately $6,759,000. Finally, Orbimed Advisors LLC bought a new stake in Jade Biosciences during the second quarter worth approximately $5,306,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.